LLY

970.55

-2.93%↓

JNJ

238.47

-2.84%↓

ABBV

231.26

-1.43%↓

NVS

159.62

-2.43%↓

AZN

196.81

-1.97%↓

LLY

970.55

-2.93%↓

JNJ

238.47

-2.84%↓

ABBV

231.26

-1.43%↓

NVS

159.62

-2.43%↓

AZN

196.81

-1.97%↓

LLY

970.55

-2.93%↓

JNJ

238.47

-2.84%↓

ABBV

231.26

-1.43%↓

NVS

159.62

-2.43%↓

AZN

196.81

-1.97%↓

LLY

970.55

-2.93%↓

JNJ

238.47

-2.84%↓

ABBV

231.26

-1.43%↓

NVS

159.62

-2.43%↓

AZN

196.81

-1.97%↓

LLY

970.55

-2.93%↓

JNJ

238.47

-2.84%↓

ABBV

231.26

-1.43%↓

NVS

159.62

-2.43%↓

AZN

196.81

-1.97%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

181.13 1.34

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

176.16

Massimo

181.99

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

EPS

2.43

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+13.77% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

852M

8.8B

Apertura precedente

179.79

Chiusura precedente

181.13

Notizie sul Sentiment di mercato

By Acuity

74%

26%

322 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mar 2026, 23:39 UTC

Azioni calde

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Utili

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Utili

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Discorsi di Mercato

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Utili

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Utili

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Utili

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Utili

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Utili

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Utili

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Discorsi di Mercato

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Utili

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Utili

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Utili

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Utili

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Utili

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Utili

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Discorsi di Mercato

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Utili

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Principali Notizie su Eventi

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Utili

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Discorsi di Mercato

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Utili

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Utili

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Utili

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Utili

Broadcom 1Q Rev $19.31B >AVGO

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

13.77% in crescita

Previsioni per 12 mesi

Media 204.3 USD  13.77%

Alto 265 USD

Basso 175 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

322 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat